By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
INVESTIGATION WILL SEEK TO DETERMINE WHETHER PERSISTENT UNDERPAYMENT FOR INNOVATIVE PHARMACEUTICAL PRODUCTS BY GERMANY IS UNREASONABLE OR DISCRIMINATORY - USTR STATEMENT